Advertisement

Diarrhea pp 177-188 | Cite as

Pancreatic Exocrine Insufficiency

  • Alphonso Brown
  • Steven D. Freedman
Chapter
Part of the Clinical Gastroenterology book series (CG)

Summary

Pancreatic enzyme replacement therapy is critical in individuals with pancreatic insufficiency. Understanding the normal physiology of pancreatic enzyme secretion and how this is deranged leading to pancreatic steatorrhea is the focus of this chapter. Several areas are detailed including how to diagnose pancreatic steatorrhea, optimal timing and use of pancreatic enzyme replacement therapy, and expected outcomes.

Key Words

Steatorrhea Pancreatic insufficiency Malabsorption Pancreatic enzyme supplement Fibrosing colonopathy 

References

  1. 1.
    DiMagno EP, Go VL, Summerskill WH. Relations between pancreatic enzyme outputs and malabsorption in severe pancreatic insufficiency. N Engl J Med 1973;88(16):813–815.CrossRefGoogle Scholar
  2. 2.
    Gaskin K, et al. Improved respiratory prognosis in patients with cystic fibrosis with normal fat absorption. J Pediatr 1982;100(6):857–862.PubMedCrossRefGoogle Scholar
  3. 3.
    Bolender RP. Stereological analysis of the guinea pig pancreas. I. Analytical model and quantitative description of nonstimulated pancreatic exocrine cells. J Cell Biol 1974;61(2):269–287.PubMedCrossRefGoogle Scholar
  4. 4.
    Sewell WA, Young JA. Secretion of electrolytes by the pancreas of the anaesthetized rat. J Physiol 1975;252(2):379–396.PubMedGoogle Scholar
  5. 5.
    Konturek SJ, Tasler J, Obtulowicz W. Effect of atropine on pancreatic responses endogenous and exogenous cholecystokinin. Am J Dig Dis 1972;17(10):911–917.PubMedCrossRefGoogle Scholar
  6. 6.
    Grundy D, Hutson D, Scratcherd T. The response of the pancreas of the anaesthetized cat to secretin before, during and after reversible vagal blockade. J Physiol 1983;342:517–526.PubMedGoogle Scholar
  7. 7.
    You CH, Rominger JM, Chey WY. Potentiation effect of cholecystokinin–octapeptide on pancreatic bicarbonate secretion stimulated by a physiologic dose of secretin in humans. Gastroenterology 1983;85(1):40–45.PubMedGoogle Scholar
  8. 8.
    Otani T, et al. Codistribution of TAP and the granule membrane protein GRAMP-92 in rat caerulein-induced pancreatitis. Am J Physiol 1998;275(5 Pt 1): G999–G1009.PubMedGoogle Scholar
  9. 9.
    Chey WY, et al. Plasma secretin concentrations in fasting and postprandial state in man. Am J Dig Dis 1978;23(11):981–988.PubMedCrossRefGoogle Scholar
  10. 10.
    Forsmark CE. The diagnosis of chronic pancreatitis. Gastrointest Endosc 2000;52(2):293–298.PubMedCrossRefGoogle Scholar
  11. 11.
    Hayakawa T, et al. Relationship between pancreatic exocrine function and histological changes in chronic pancreatitis. Am J Gastroenterol 1992;87(9): 1170–1174.PubMedGoogle Scholar
  12. 12.
    Heij HA, et al. Relationship between functional and histological changes in chronic pancreatitis. Dig Dis Sci 1986;31(10):1009–1013.PubMedCrossRefGoogle Scholar
  13. 13.
    Waye JD, Adler M, Dreiling DA. The pancreas: a correlation of function and structure. Am J Gastroenterol 1978;69(2):176–181.PubMedGoogle Scholar
  14. 14.
    Soudah HC, et al. Cholecystokinin at physiological levels evokes pancreatic enzyme secretion via a cholinergic pathway. Am J Physiol 1992;263(1 Pt 1): G102–G107.PubMedGoogle Scholar
  15. 15.
    Adler G, et al. Interaction of the cholinergic system and cholecystokinin in the regulation of endogenous and exogenous stimulation of pancreatic secretion in humans. Gastroenterology 1991;100(2):537–543.PubMedGoogle Scholar
  16. 16.
    Tang F, et al. Studies on the pleomorphism of trachoma inclusion. Wei Sheng Wu Xue Bao 1993;33(5):365–367.PubMedGoogle Scholar
  17. 17.
    Li Y, Zhu J, Owyang C. Electrical physiological evidence for high and low-affinity vagal CCK-A receptors. Am J Physiol 1999;277(2 Pt 1):G469–G477.PubMedGoogle Scholar
  18. 18.
    Ji B, et al. Human pancreatic acinar cells lack functional responses to cholecystokinin and gastrin. Gastroenterology 2001;121(6):1380–1390.PubMedCrossRefGoogle Scholar
  19. 19.
    Miyasaka K, et al. Amylase secretion from dispersed human pancreatic acini: neither cholecystokinin a nor cholecystokinin B receptors mediate amylase secretion in vitro. Pancreas 2002;25(2):161–165.PubMedCrossRefGoogle Scholar
  20. 20.
    Pandol SJ. Neurohumoral control of exocrine pancreatic secretion. Curr Opin Gastroenterol 2003;19(5):443–446.PubMedCrossRefGoogle Scholar
  21. 21.
    Brooks AM, Grossman MI. Postprandial pH and neutralizing capacity of the proximal duodenum in dogs. Gastroenterology 1970;59(1):85–89.PubMedGoogle Scholar
  22. 22.
    Hanssen LE. Pure synthetic bile salts release immunoreactive secretin in man. Scand J Gastroenterol 1980;15(4):461–463.PubMedCrossRefGoogle Scholar
  23. 23.
    Valnes K, et al. Plasma concentration of secretin and gastric secretion following intraduodenal calcium infusion in man. Scand J Gastroenterol 1980;15(7): 881–885.PubMedCrossRefGoogle Scholar
  24. 24.
    Schaffalitzky de Muckadell OB, et al. Pancreatic response and plasma secretin concentration during infusion of low dose secretin in man. Scand J Gastroenterol 1978;13(3):305–311.CrossRefGoogle Scholar
  25. 25.
    Steward MC, Ishiguro H, Case RM. Mechanisms of bicarbonate secretion in the pancreatic duct. Annu Rev Physiol 2005;67:377–409.PubMedCrossRefGoogle Scholar
  26. 26.
    Li Y, et al. Intestinal serotonin acts as paracrine substance to mediate pancreatic secretion stimulated by luminal factors. Am J Physiol Gastrointest Liver Physiol 2001;281(4):G916–G923.PubMedGoogle Scholar
  27. 27.
    Zhu JX, et al. Intestinal serotonin acts as a paracrine substance to mediate vagal signal transmission evoked by luminal factors in the rat. J Physiol 2001;530 (Pt 3):431–442.PubMedCrossRefGoogle Scholar
  28. 28.
    Li Y, Owyang C. Somatostatin inhibits pancreatic enzyme secretion at a central vagal site. Am J Physiol 1993;265(2 Pt 1):G251–G257.PubMedGoogle Scholar
  29. 29.
    Vinnitsky VB, Glinsky GV. Role of the binding of neuropeptides to blood plasma proteins in the control of their blood–brain barrier passage. Ann N Y Acad Sci 1987;496:278–291.PubMedCrossRefGoogle Scholar
  30. 30.
    Jung G, Louie DS, Owyang C. Pancreatic polypeptide inhibits pancreatic enzyme secretion via a cholinergic pathway. Am J Physiol 1987;253(5 Pt 1): G706–G710.PubMedGoogle Scholar
  31. 31.
    Tatemoto K. Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci USA 1982;79(8):2514–2518.PubMedCrossRefGoogle Scholar
  32. 32.
    Taylor IL. Distribution and release of peptide YY in dog measured by specific radioimmunoassay. Gastroenterology 1985;88(3):731–737.PubMedGoogle Scholar
  33. 33.
    Layer P, et al. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology 1994;107(5):1481–1487.PubMedGoogle Scholar
  34. 34.
    Layer P, et al. Cholinergic regulation of phase II interdigestive pancreatic secretion in humans. Pancreas 1993;8(2):181–188.PubMedCrossRefGoogle Scholar
  35. 35.
    DiMagno EP, et al. Fate of orally ingested enzymes in pancreatic insufficiency. Comparison of two dosage schedules. N Engl J Med 1977;296(23):1318–1322.PubMedCrossRefGoogle Scholar
  36. 36.
    Keller J, Holst JJ, Layer P. Inhibition of human pancreatic and biliary output but not intestinal motility by physiological intraileal lipid loads. Am J Physiol Gastrointest Liver Physiol 2006;290(4):G704–G709.PubMedCrossRefGoogle Scholar
  37. 37.
    Slaff J, et al. Protease-specific suppression of pancreatic exocrine secretion. Gastroenterology 1984;87(1):44–52.PubMedGoogle Scholar
  38. 38.
    Guarner L, et al. Fate of oral enzymes in pancreatic insufficiency. Gut 1993; 34(5):708–712.PubMedCrossRefGoogle Scholar
  39. 39.
    Nakamura T, et al. Study of gastric emptying in patients with pancreatic diabetes (chronic pancreatitis) using acetaminophen and isotope. Acta Gastroenterol Belg 1996;59(3):173–177.PubMedGoogle Scholar
  40. 40.
    Regan PT, et al. Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency. N Engl J Med 1977;297(16):854–858.PubMedCrossRefGoogle Scholar
  41. 41.
    Layer P, Holtmann G. Pancreatic enzymes in chronic pancreatitis. Int J Pancreatol 1994;15(1):1–11.PubMedGoogle Scholar
  42. 42.
    Gullo L, et al. Cardiovascular lesions in chronic pancreatitis: a prospective study. Dig Dis Sci 1982;27(8):716–722.PubMedCrossRefGoogle Scholar
  43. 43.
    Smyth RL, et al. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994;343(8889):85–86.PubMedCrossRefGoogle Scholar
  44. 44.
    Lebenthal E. High strength pancreatic exocrine enzyme capsules associated with colonic strictures in patients with cystic fibrosis: “more is not necessarily better”. J Pediatr Gastroenterol Nutr 1994;18(4):423–425.PubMedCrossRefGoogle Scholar
  45. 45.
    FitzSimmons SC, et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997;336(18): 1283–1289.PubMedCrossRefGoogle Scholar
  46. 46.
    Lebenthal E, Rolston DD, Holsclaw DS Jr. Enzyme therapy for pancreatic insufficiency: present status and future needs. Pancreas 1994;9(1):1–12.PubMedCrossRefGoogle Scholar
  47. 47.
    Russell RM, et al. Impairment of folic acid absorption by oral pancreatic extracts. Dig Dis Sci 1980;25(5):369–373.PubMedCrossRefGoogle Scholar
  48. 48.
    Stapleton FB, et al. Hyperuricosuria due to high-dose pancreatic extract therapy in cystic fibrosis. N Engl J Med 1976;295(5):246–248.PubMedCrossRefGoogle Scholar
  49. 49.
    Zentler-Munro PL, et al. Therapeutic potential and clinical efficacy of acid-resistant fungal lipase in the treatment of pancreatic steatorrhoea due to cystic fibrosis. Pancreas 1992;7(3):311–319.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Alphonso Brown
    • 1
  • Steven D. Freedman
    • 1
  1. 1.The Pancreas Center: Beth Israel Deaconess MedicalBostonUSA

Personalised recommendations